Very few new molecular entities in active clinical development are readily bioavailable, and when dosed at escalated levels, even these may not be sufficiently absorbed. Learn how spray-dried amorphous dispersion might help.
Not yet a member of BioProcess Online? Register today.
Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.
You might also want to: